L3VLUP
ProSign in

PRME in the 13F filings

Prime Medicine Inc · CUSIP 74168J101

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 18 Oct 2023
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 2 listed it in both
Shares listed
3,069,162
combined, among listed positions
Reported value
$29m
combined, at the quarter end

Managers listing PRME in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
ARK Investment Management LLC2,622,429$25m0.19%Added+173,23018 Oct 2023 (the filing on sec.gov)
Moore Capital Management LP446,733$4.3m0.08%Held014 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

01234Q4 2022Q2 2023Q4 2023Q2 2024Q4 2024Q2 2025Q4 2025Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
PRME by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20222$40mn.a.n.a.
Q1 20232$30mn.a.n.a.
Q2 20232$42mn.a.n.a.
Q3 20232$29mn.a.n.a.
Q4 20232$29m21
Q1 20243$51m30
Q2 20243$38m10
Q3 20243$27m01
Q4 20243$19m01
Q1 20253$8.6m01
Q2 20253$8.8m01
Q3 20254$76m30
Q4 20254$35m1515
Q1 20264$38m1113
Q2 20263$37m139

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

PRME and GILD →PRME and AMGN →PRME and ARGX →Choose a stock to compare with PRME →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own PRME, latest filings →Back to the 13F Explorer →